Addyi (Flibanserin) Overdose and Accidental Excess Dose: What to Know and How to Respond

How Flibanserin Works: The Pharmacology Behind Overdose Risk

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that simultaneously increases dopamine and norepinephrine activity in the prefrontal cortex. This mixed serotonergic-dopaminergic mechanism, originally explored as an antidepressant, was repurposed after clinical trials revealed its effect on sexual desire in premenopausal women with hypoactive sexual desire disorder (HSDD) [1]. Understanding this mechanism matters because the same receptor activity that restores desire also explains the drug's dose-dependent side effects.

Serotonin and Dopamine: A Balancing Act

By activating 5-HT1A receptors, flibanserin reduces serotonin's inhibitory tone on sexual motivation circuits. Simultaneously, blocking 5-HT2A receptors disinhibits downstream dopamine and norepinephrine release in the medial prefrontal cortex [2]. This dual action differs from SSRIs, which raise serotonin broadly and often suppress libido.

Why the CNS Effects Are Dose-Dependent

At the approved 100 mg bedtime dose, these receptor interactions produce mild sedation and modest blood-pressure lowering. In overdose, the amplified serotonergic agonism and dopaminergic surge produce exaggerated CNS depression, orthostatic hypotension, and the risk of syncope that dominates the clinical picture [3].

Pharmacokinetic Factors That Shape Overdose Severity

Flibanserin reaches peak plasma concentration (Tmax) approximately 0.75 to 1 hour after oral dosing. Its elimination half-life averages 11 hours, but active metabolites extend pharmacodynamic effects. Hepatic metabolism runs almost entirely through [CYP3A4](https://pubmed.ncbi.nlm.nih.gov/26## What Happens During a Flibanserin Overdose

A flibanserin overdose produces a predictable constellation of symptoms driven by excessive serotonin-1A agonism and dopamine-norepinephrine disinhibition. The FDA prescribing information documents the clinical picture observed in premarketing overdose cases and dedicated pharmacodynamic studies [3].

Hypotension and Syncope

The most dangerous acute effect is a sharp drop in blood pressure. In FDA-reviewed interaction studies, even a single supratherapeutic dose combined with moderate alcohol produced symptomatic hypotension requiring clinical intervention in 25% of subjects [4]. Syncope (fainting with loss of consciousness) can occur within 1 to 3 hours of ingestion, particularly if the patient stands or changes position rapidly.

CNS Depression

Excessive sedation, somnolence, and dizziness dominate the neurological picture. Patients may appear disoriented or difficult to arouse. At high doses, the sedation can progress to obtundation, though respiratory depression has not been a prominent feature in reported cases [3].

Nausea and Fatigue

Gastrointestinal symptoms, primarily nausea, occur frequently even at therapeutic doses. In the BEGONIA trial (N=1,087), nausea affected 11.2% of flibanserin-treated participants vs. 4.4% on placebo [1]. At supratherapeutic doses, nausea intensifies and may be accompanied by vomiting.

What Has NOT Been Reported

Unlike tricyclic antidepressant overdoses, flibanserin has not been associated with cardiac arrhythmias, QT prolongation, or seizures in documented cases. The drug does not significantly bind to muscarinic, histaminergic H1, or adrenergic alpha-1 receptors at concentrations achievable in overdose, which limits anticholinergic toxicity [2].

Emergency Treatment Protocol for Flibanserin Overdose

There is no specific antidote for flibanserin. Management follows standard toxicology principles with targeted support for the drug's known hemodynamic and CNS effects [3].

Initial Assessment and Stabilization

Place the patient supine with legs elevated if hypotensive. Obtain vital signs including orthostatic blood pressure measurements. Establish IV access and initiate crystalloid fluid resuscitation (normal saline or lactated Ringer's, 500 mL to 1 L bolus in adults) for systolic blood pressure below 90 mmHg [5].

Airway and Breathing

Assess the level of consciousness using the Glasgow Coma Scale. While respiratory depression is uncommon, deeply sedated patients with a GCS below 8 require airway protection. Supplemental oxygen should be applied to any patient with altered mental status.

Vasopressor Support

If hypotension does not respond to 2 L of IV crystalloid, initiate vasopressor therapy. Norepinephrine (starting at 0.1 mcg/kg/min, titrated to MAP above 65 mmHg) is a reasonable first choice given flibanserin's mechanism [5]. Avoid pure alpha-agonists like phenylephrine alone, since the drug's effects include central catecholamine modulation.

Decontamination Considerations

Activated charcoal (1 g/kg, maximum 50 g) may be considered if the patient presents within 1 hour of a large ingestion and has a protected airway. Given flibanserin's rapid absorption (Tmax under 1 hour), the window for effective decontamination is narrow [3]. Gastric lavage is not routinely recommended.

Monitoring Duration

Because flibanserin's half-life is approximately 11 hours, patients with significant overdoses should be monitored for a minimum of 12 to 24 hours. Orthostatic vital signs should be checked every 2 hours until the patient can stand and ambulate without dizziness or blood pressure drops exceeding 20 mmHg systolic [5].

The Alcohol-Flibanserin Interaction: Why Co-Ingestion Is the Highest-Risk Scenario

The FDA required a boxed warning specifically addressing concurrent alcohol use with flibanserin. This is not a theoretical concern.

The Interaction Study Data

In a dedicated pharmacodynamic study conducted during the REMS development process, combining flibanserin 100 mg with 0.4 g/kg ethanol (roughly two standard drinks) caused clinically significant hypotension and syncope requiring medical intervention in approximately 25% of female subjects. Some participants required IV fluids and prolonged observation [4]. Systolic blood pressure dropped below 80 mmHg in several cases.

Why Alcohol Amplifies the Risk

Alcohol independently causes vasodilation and impairs baroreceptor reflexes. Flibanserin's 5-HT1A agonism adds a second vasodepressive signal through central autonomic pathways. The combined effect is not additive; it is synergistic. A patient who tolerates either substance alone may develop profound hypotension when they overlap [4].

Clinical Implication for Overdose Scenarios

When evaluating a potential flibanserin overdose, always ask about alcohol consumption in the preceding 6 hours. Co-ingestion with even moderate amounts of alcohol transforms a potentially benign overdose into a hemodynamically significant event requiring more aggressive fluid resuscitation and longer monitoring [3].

Drug Interactions That Mimic or Worsen Overdose

Several drug classes can effectively create a pharmacokinetic overdose by raising flibanserin plasma concentrations well above the intended therapeutic range.

Strong CYP3A4 Inhibitors

Concomitant use of strong CYP3A4 inhibitors with flibanserin is contraindicated. Ketoconazole increased flibanserin AUC by approximately 4.5-fold in pharmacokinetic studies [3]. Other strong CYP3A4 inhibitors that carry the same risk include itraconazole, clarithromycin, ritonavir, nelfinavir, and conivaptan.

Moderate CYP3A4 Inhibitors

Drugs like fluconazole, erythromycin, diltiazem, verapamil, and grapefruit juice (consumed regularly) raise flibanserin exposure by roughly 2-fold. The FDA labeling recommends a reduced starting dose or avoidance depending on the specific inhibitor [3]. A patient taking a moderate CYP3A4 inhibitor who then takes the standard 100 mg dose may experience effects equivalent to a 200 mg dose.

Serotonergic Medications

Because flibanserin acts on serotonin receptors, combining it with SSRIs, SNRIs, triptans, or MAOIs raises theoretical serotonin syndrome risk. The BEGONIA trial excluded patients on serotonergic drugs, so interaction data is limited [1]. Clinicians managing a suspected overdose in a patient taking both flibanserin and an SSRI should monitor for serotonin syndrome signs: clonus, hyperthermia, agitation, and hyperreflexia [6].

The Flibanserin REMS Program and Overdose Prevention

The FDA approved flibanserin with a Risk Evaluation and Mitigation Strategy (REMS) specifically because of the syncope and severe hypotension risk, not because of traditional overdose concern [7].

What the REMS Requires

Prescribers must complete a training module and enroll in the REMS program before writing flibanserin prescriptions. Pharmacies must also certify. Patients receive a counseling document that emphasizes the alcohol contraindication, the bedtime-only dosing requirement, and the need to avoid CYP3A4 inhibitors [7].

How the REMS Reduces Overdose Risk

The REMS effectively limits prescribing to clinicians who understand the drug's interaction profile. Pharmacy-level certification adds a second checkpoint. In 2019, the FDA modified the REMS after a citizen petition, removing the requirement for prescribers to assess alcohol use at each visit but maintaining the core prescriber/pharmacy certification [8].

Practical Prevention Measures

Patients should receive clear guidance: take exactly 100 mg at bedtime, never double a missed dose, and abstain from alcohol entirely. If a dose is missed, skip it and take the next scheduled dose the following evening. Taking a double dose to "catch up" is the most common accidental overdose scenario [3].

Special Populations and Overdose Considerations

Hepatic Impairment

Flibanserin is contraindicated in patients with hepatic impairment of any severity. The drug undergoes extensive first-pass hepatic metabolism, and impaired clearance results in plasma concentrations that can reach 4.4-fold higher than in patients with normal liver function [3]. A standard 100 mg dose in a patient with unrecognized cirrhosis may produce overdose-level drug exposure.

Renal Impairment

Mild to moderate renal impairment does not significantly alter flibanserin pharmacokinetics. The drug is less than 1% renally excreted, so dose adjustment is not required for kidney disease alone [3]. Severe renal impairment (CrCl <30 mL/min) has not been formally studied.

CYP2C19 Poor Metabolizers

Approximately 2 to 5% of Caucasians and 12 to 20% of East Asian populations are CYP2C19 poor metabolizers. These patients may have flibanserin exposures approximately 1.5 to 2-fold higher than extensive metabolizers [3]. While this does not reach the magnitude of CYP3A4 inhibitor interactions, it can lower the threshold for adverse effects and should be considered when evaluating overdose severity.

When to Call Poison Control vs. When to Go to the Emergency Department

Not every accidental extra dose requires an ER visit. The decision depends on the clinical picture and co-ingestants.

Poison Control (1-800-222-1222) Is Appropriate When

The patient took one extra dose (200 mg total), has no alcohol on board, is not taking CYP3A4 inhibitors, and feels only mildly drowsy. Poison Control toxicologists can provide real-time guidance and may recommend home observation with specific monitoring instructions [9].

Emergency Department Evaluation Is Needed When

The patient took more than two times the prescribed dose, consumed any amount of alcohol within 6 hours of dosing, is taking a moderate or strong CYP3A4 inhibitor, experiences syncope or near-syncope, or has a systolic blood pressure below 90 mmHg. Any loss of consciousness warrants immediate emergency evaluation [3].

What to Bring to the ED

Bring the medication bottle (to confirm the exact product and remaining pill count), a list of all current medications, and an honest accounting of alcohol consumed. This information allows the emergency physician to calculate the approximate ingested dose and identify dangerous co-ingestants.

Long-Term Considerations After an Overdose Event

Restarting Flibanserin

After a resolved overdose with full recovery, the decision to restart flibanserin depends on the cause. If the overdose was accidental (missed-dose doubling), restarting at 100 mg with reinforced patient education is reasonable after the drug has fully cleared (at least 3 days, accounting for a 5 half-life washout). If the overdose involved intentional self-harm, psychiatric evaluation should precede any reinitiation [3].

Monitoring After Discharge

No specific lab monitoring is required post-overdose. Orthostatic blood pressure should be confirmed normal before discharge. Patients should avoid driving or operating machinery for 24 hours after symptom resolution due to residual CNS effects [3].

The American Association of Poison Control Centers (AAPCC) annual report categorizes flibanserin exposures as low-volume relative to other CNS-active medications, with most cases managed at home or with brief observation [9]. The 2023 AAPCC data recorded fewer than 200 flibanserin exposure calls nationally, reflecting the drug's limited prescribing volume under the REMS framework.